Trevi Therapeutics, Inc. financial data

Symbol
TRVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
195 Church Street, 14 Th Floor, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.03K % -24.7%
Debt-to-equity 11.8 % +29.8%
Return On Equity -64.5 % -105%
Return On Assets -57.7 % -99.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.7M shares +40.2%
Common Stock, Shares, Outstanding 93.6M shares +37.1%
Entity Public Float 180M USD +70.2%
Common Stock, Value, Issued 94K USD +38.2%
Weighted Average Number of Shares Outstanding, Basic 102M shares +2.97%
Weighted Average Number of Shares Outstanding, Diluted 102M shares +2.97%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 39.4M USD +66.3%
General and Administrative Expense 12.1M USD +18.6%
Operating Income (Loss) -51.5M USD -51.9%
Nonoperating Income (Expense) 3.58M USD -25.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -47.9M USD -64.8%
Income Tax Expense (Benefit) -30K USD +6.25%
Net Income (Loss) Attributable to Parent -47.9M USD -64.8%
Earnings Per Share, Basic -0.47 USD/shares -62.1%
Earnings Per Share, Diluted -0.47 USD/shares -62.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34.1M USD +5.25%
Marketable Securities, Current 73.5M USD +45.4%
Other Assets, Current 867K USD -9.22%
Assets, Current 109M USD +25%
Property, Plant and Equipment, Net 157K USD -27.3%
Operating Lease, Right-of-Use Asset 915K USD -19.5%
Other Assets, Noncurrent 243K USD -18.2%
Assets 111M USD +24%
Accounts Payable, Current 3.41M USD +88.7%
Accrued Liabilities, Current 6.81M USD +83.6%
Liabilities, Current 10.5M USD +80.4%
Operating Lease, Liability, Noncurrent 747K USD -25.4%
Liabilities 11.3M USD +64.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 61K USD
Retained Earnings (Accumulated Deficit) -287M USD -20%
Stockholders' Equity Attributable to Parent 99.6M USD +20.7%
Liabilities and Equity 111M USD +24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD -27.7%
Net Cash Provided by (Used in) Financing Activities -28K USD +98.4%
Net Cash Provided by (Used in) Investing Activities -8.09M USD -190%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 93.6M shares +37.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.6M USD -1881%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.1M USD +5.25%
Deferred Tax Assets, Valuation Allowance 82.4M USD +18.6%
Deferred Tax Assets, Gross 82.8M USD +18.2%
Operating Lease, Liability 1M USD -15.5%
Payments to Acquire Property, Plant, and Equipment 57K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47.8M USD -65.1%
Lessee, Operating Lease, Liability, to be Paid 1.19M USD -20.3%
Property, Plant and Equipment, Gross 385K USD +10%
Operating Lease, Liability, Current 254K USD +38%
Lessee, Operating Lease, Liability, to be Paid, Year Two 368K USD +5.44%
Lessee, Operating Lease, Liability, to be Paid, Year One 349K USD +15.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 188K USD -38.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 377K USD +2.45%
Deferred Tax Assets, Operating Loss Carryforwards 53.8M USD +6.94%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 95K USD -74.8%
Operating Lease, Payments 303K USD +31.2%
Additional Paid in Capital 387M USD +20.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 35K USD +84.2%
Interest Expense 9K USD -99.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%